← ANALYST RATINGS · TIPRANKS
Quest Diagnostics (DGX): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy4 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $256, the highest $265, the lowest $245. The average is +8.9% from the last price of $235.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $250 → $260+4.0% | Buy | +10.6% | Reiterated | 07.10.26on TipRanks 03:55 | −0.3%next day +2.1% · 5 days +3.8% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $262 → $261−0.4% | Buy | +11.1% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $262 → $253−3.4% | Hold | +7.7% | Downgrade | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $255 → $254−0.4% | Hold | +8.1% | Downgrade | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $238 → $244+2.5% | Hold | +3.8% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $256 → $257+0.4% | Buy | +9.4% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $271 → $262−3.3% | Buy | +11.5% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| David S Macdonald★★★★★★★★★★#400 · hits 63% · avg +13.2% | Truist Financial | $250 → $260+4.0% | Hold | +10.6% | Reiterated | 22.09.26on TipRanks Sep 21 07:25 | −2.2%next day −4.1% · 5 days −1.9% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $232 → $245+5.6% | Hold | +4.3% | Reiterated | 08.09.26on TipRanks 08:20 | −0.1%next day +0.4% · 5 days +6.0% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $260 | Buy | +10.6% | Reiterated | 19.08.26on TipRanks 07:25 | +2.1%next day +0.7% · 5 days +1.7% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | $260 | Buy | +10.6% | Reiterated | 28.07.26on TipRanks Jul 29 11:00 | +1.5%next day +1.2% · 5 days −5.1% | ↗ |
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $260 | Buy | +10.6% | Reiterated | 28.07.26on TipRanks Jul 29 08:20 | +1.5%next day +1.2% · 5 days −5.1% | ↗ |
| Lisa Gill★★★★★★★★★★#1237 · hits 58% · avg +9.0% | J.P. Morgan | $220 → $250+13.6% | Hold | +6.4% | Assigned | 28.07.26on TipRanks 08:05 | +1.5%next day +1.2% · 5 days −5.1% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $265 | Buy | +12.8% | Reiterated | 24.07.26on TipRanks 10:17 | −0.1%next day +1.7% · 5 days +1.2% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $236 → $255+8.1% | Hold | +8.5% | Reiterated | 24.07.26on TipRanks 07:26 | −0.1%next day +1.7% · 5 days +1.2% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $225 → $245+8.9% | Buy | +4.3% | Reiterated | 23.07.26on TipRanks 21:16 | −0.1%next day +1.7% · 5 days +1.2% | ↗ |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Buy | — | Reiterated | 23.07.26on TipRanks 21:16 | −0.1%next day +1.7% · 5 days +1.2% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $210 | Hold | −10.6% | Reiterated | 20.04.26on TipRanks 11:15 | +0.9%next day +5.1% · 5 days −0.7% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $190 → $215+13.2% | Hold | −8.5% | Reiterated | 11.02.26on TipRanks Feb 10 23:20 | +2.0%next day +0.4% · 5 days −2.2% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $190 → $200+5.3% | Hold | −14.9% | Reiterated | 27.10.25on TipRanks 07:15 | −2.2%next day −1.4% · 5 days −0.5% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | $203 → $210+3.4% | Buy | −10.6% | Reiterated | 22.10.25on TipRanks Oct 21 13:20 | −3.0%next day −1.4% · 5 days −5.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Quest Diagnostics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $255 at a price of $233 (+9.4%); now: $256 at $235 (+8.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 7 | 12 | 13 | 12 | 3 |
| Hold | 6 | 6 | 7 | 6 | 8 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 22.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.87 (from $2.82 to $2.94). Last quarter: $3.12.
Sales
Next quarter’s sales estimate — $3.0B (from $3.0B to $3.1B). Last quarter: $3.0B.
Best top-analyst consensus in the sector · Healthcare
About Quest Diagnostics
- CEO: James E. Davis
- Employees: 51,500
- 500 Plaza Drive, Secaucus, NJ, 07094, US
- www.questdiagnostics.com
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Data from the stock’s TipRanks forecast page, read 46 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗